CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.